Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced results from its Phase 2 RECONNOITER trial of AISA-021 (cilnidipine), a novel ...
Al-Aly and his colleagues found that people starting the GLP-1 drugs had lower risks of developing addiction to multiple ...
Ozempic (R) was approved by Health Canada in 2018. Ozempic (R) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control.
Canada: Researchers have found in a new randomized clinical trial that a 4-week vancomycin pulse and taper regimen showed a ...
Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for ...
GLP-1s could help curb substance abuse – including alcohol and opioids, new study finds - Increasingly popular GLP-1 drugs ...
Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 monthsEB613 single tablet final commercial ...
A new study found GLP-1 drugs were associated with 50% fewer substance-related deaths, 39% fewer drug overdoses, and 26% ...
Introduction Individuals experiencing moderate to severe mental illness have low rates of workforce inclusion, with a consequence of high welfare dependency, affecting both societal costs and health.
A team of University of Michigan investigators reported that their multimodal, chronic disease self-management support program for people living with glaucoma, SEE, was linked to an approximate 20% ...
RASolute 302 Phase 3 catalyst, cash runway, and valuation risks for daraxonrasib. Read more macro analysis here.
Morning Overview on MSN
Brain scans on psychedelics reveal how wild visual hallucinations form
A growing body of neuroimaging research is pinpointing exactly how psychedelic drugs hijack the brain’s visual system to produce vivid hallucinations, even when a person’s eyes are closed. Studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results